Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis

Duan, Chenyang; Liu, Mengying; Zhang, Zhuohang; Ma, Kui; Bie, Ping

doi:10.1186/1477-7819-11-190

Cited by 66 publications

(51 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results corresponded with those of a previous meta-analysis in which VASCULAR AND INTERVENTIONAL RADIOLOGY: Radiofrequency Ablation versus Resection for Small Hepatocellular Carcinoma Kang et al RF ablation and hepatic resection were compared (40). Our study had several limitations.…”

Section: Vascular and Interventional Radiology: Radiofrequency Ablatisupporting

confidence: 88%

Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection—Propensity Score Analyses of Long-term Outcomes

Kang¹,

Kim²,

Rhim³

et al. 2015

Radiology

135

View full text Add to dashboard Cite

show abstract

Section: Vascular and Interventional Radiology: Radiofrequency Ablatisupporting

confidence: 88%

Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection—Propensity Score Analyses of Long-term Outcomes

Kang¹,

Kim²,

Rhim³

et al. 2015

Radiology

135

View full text Add to dashboard Cite

show abstract

“…An idea simultaneously developed in four labs across the world 12,13,14,15 it was the reverse of stereotaxy; instead of finding a location on an image and moving to it, the present surgical position and trajectory were digitized and the location displayed on the images. One remarkable aspect to this development was that it arose from surgeon/engineer teams.…”

Section: Examplesmentioning

confidence: 99%

Engineering therapeutic processes: from research to commodity

Galloway

2014

SPIE Proceedings

View full text Add to dashboard Cite

Three of the most important forces driving medical care are: patient specificity, treatment specificity and the move from discovery to design. Engineers while trained in specificity, efficiency, and design are often not trained in either biology or medical processes. Yet they are increasing critical to medical care. For example, modern medical imaging at US hospitals generates 1 exabyte (10^18 bytes) of data per year clearly beyond unassisted human analysis. It is not desirable to involve engineers in the acquisition, storage and analysis of this data, it is essential. While in the past we have nibbled around the edges of medical care, it is time and perhaps past time to insert ourselves more squarely into medical processes, making them more efficient, more specific and more robust. This requires engineers who understand biology and physicians who are willing to step away from classic medical thinking to try new approaches. But once the idea is proven in a laboratory, it must move into use and then into common practice. This requires additional engineering to make the process robust to noisy data and imprecise practices as well as workflow analysis to get the new technique into operating and treatment rooms. True innovation and true translation will require physicians, engineers, other medical stakeholders and even corporate involvement to take a new, important idea and move it not just to a patient but to all patients.

show abstract

“…Surgical resection is associated with greater OS and DFS rates than RFA, according to the results of a 2013 systematic review and meta-analysis covering two RCTs and 10 non-RCTs; however, ablation is associated with fewer post-treatment complications and shorter hospital stays [58]. Conversely, there are data from other RCTs showing comparable long-term survival outcomes with resection and RFA [59,60].…”

Section: Consensus Recommendationsmentioning

confidence: 99%

Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma

et al. 2015

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is particularly prevalent in Hong Kong because of the high prevalence of chronic hepatitis B (CHB) infection; HCC is the fourth commonest cancer in men and the seventh commonest in women, and it is the third leading cause of cancer death in Hong Kong. The full spectrum of treatment modalities for HCC is available locally; however, there is currently no local consensus document detailing how these modalities should be used. Summary: In a series of meetings held between May and October 2013, a multidisciplinary group of Hong Kong clinicians − liver surgeons, medical oncologists, clinical oncologists, hepatologists, and interventional radiologists − convened to formulate local recommendations on HCC management. These recommendations consolidate the most current evidence pertaining to HCC treatment modalities, together with the latest thinking of practicing clinicians engaged in HCC management, and give detailed guidance on how to deploy these modalities effectively for patients in various disease stages. Key messages: Distinct from other regional guidelines, these recommendations provide guidance on the use of antiviral therapy to reduce the incidence of HCC in CHB patients with cirrhosis and to reduce recurrence of CHB-related HCC.

show abstract

Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis

Cited by 66 publications

References 33 publications

Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection—Propensity Score Analyses of Long-term Outcomes

Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection—Propensity Score Analyses of Long-term Outcomes

Engineering therapeutic processes: from research to commodity

Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About